Anti-Suicide Drugs Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-01-16　·　151 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 4.11 Bn
2033 年預估規模: USD 5.00 Bn
年複合成長率 CAGR: 2.8%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-01-16頁數 151報告編號 CMI10

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Anti-Suicide Drugs Market, By Drug Class (Anti-Depressant and Anti-Anxiety Drugs, Anti-Psychotic Drugs, NMDA Antagonist, Antibiotic Analog) By Drug Class: Anti depressants & anti anxiety drugs, Anti psychotic drugs, NMDA antagonists, Antibiotic analogs ), By Application (Hospitals, Retail Pharmacies, Online Pharmacies) , By Geography (North America, Latin America, Europe, Asia Pacific, Middle East and Africa)

報告摘要

Suicidal thoughts can be aroused due to various underlying factors such as financial burden, social issues or drug side effects. Treatment for suicidal thoughts includes psychotherapy, medications, addiction treatment, and family support. Anti-depressants and anti-psychotics are the most widely used medications for treating suicidal tendencies. According to the World Health Organization (WHO), over 800,000 people die due to suicide annually. Development of an effective anti-suicidal drug could be a major breakthrough in reducing the death toll. Currently, non-profit organizations such as Stop Suicide, Stop Youth Suicide, and American Foundation for Suicide Prevention are providing moral and social support to people with reported suicidal thoughts. This however, is ineffective until the organization is alerted of the person at risk for suicide. Market Dynamics Off-label use of these drugs for suicidal ideation has been a practice for years, as there are no approved anti-suicide specific drug yet. However, the dynamics is expected to change in the following few years with the launch of first oral therapeutic drug for acute suicidal ideation. This would disrupt the use of antidepressants and anti-psychotic drugs for the treatment of suicidal tendencies. Suicidal incidences are high in low and middle income countries according to the WHO 2016 statistics. Although the incidence in Asia, East Africa, and Eastern European region is high, these regions lag in terms of availability of affordable medications and healthcare facilities. Therefore developed economies of North America and Western Europe are key target regions for manufacturers in the near future. Rampant economic growth and projected strengthening of the healthcare infrastructure in emerging economies in towards the first half of the following decade is projected to shift the focus of these companies towards highly populous regions of India and China in the long run. Key features of the study • This report provides in-depth analysis of the anti-suicide drugs and provides market size (USD Bn) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2026 – 2033, considering 2025 as the base year • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players • It profiles leading players in the global anti-suicide drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans • Key companies covered as a part of this study include Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., H. Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson • Insights from this report would allow marketers and the management of companies to make informed decision with respect to their future product launch, competitive scenario, geographic expansion, and marketing tactics • The global anti-suicide devices market report caters to various stakeholders in this industry, including investors, drug manufacturers, distributors and suppliers, research and consulting firms, new entrants, and financial analysts • Various strategy matrices used in analyzing the anti-suicide drugs market would provide stakeholders vital inputs to make strategic decisions accordingly Market Segmentation • By Drug Class o Anti depressants & anti anxiety drugs o Anti psychotic drugs o NMDA antagonists o Antibiotic analogs • By Application o Hospitals o Retail Pharmacies o Online Pharmacies • By Region o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East & Africa  GCC Countries  Israel  Rest of Middle East & Africa • Anti-Suicide Drugs Market Companies o Pfizer, Inc. o AstraZeneca plc o Eli Lilly and Company o Allergan plc o GlaxoSmithKline plc o Merck & Co., Inc. o Lundbeck A/S o NeuroRx, Inc. o Johnson & Johnson

目錄 Table of Contents

Table of Contents 1. Research Objective and assumption o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snippet, By Drug Class  Market Snippet, By Distribution Channel  Market Snippet, By Geography o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Epidemiology o Healthcare Spending o PEST Analysis o Pipeline Analysis o Anti-Suicide Prevention Campaigns and Programs 4. Global Anti-Suicide Drugs Market, By Drug Class, 2026 - 2033 (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-O-Y Growth Analysis, 2026 - 2033  Segment Trends o Anti-Depressant and Anti-Anxiety Drugs  Introduction  Market Size and Forecast, and Y-O-Y Growth, 2026 - 2033, (USD Bn) o Anti-Psychotic Drugs  Introduction  Market Size and Forecast, and Y-O-Y Growth, 2026 - 2033, (USD Bn) o NMDA Antagonist  Introduction  Market Size and Forecast, and Y-O-Y Growth, 2026 - 2033, (USD Bn) o Antibiotic Analog  Introduction  Market Size and Forecast, and Y-O-Y Growth, 2026 - 2033, (USD Bn) 5. Global Anti-Suicide Drugs Market, By Distribution Channel, 2026 - 2033 (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-O-Y Growth Analysis, 2026 - 2033 o Hospitals  Introduction  Market Size and Forecast, and Y-O-Y Growth, 2026 - 2033, (USD Bn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-O-Y Growth, 2026 - 2033, (USD Bn) o Online Pharmacies  Introduction  Market Size and Forecast, and Y-O-Y Growth, 2026 - 2033, (USD Bn) 6. Global Anti-Suicide Drugs Market, By Geography, 2026 - 2033 (USD Bn) o Introduction  Market Share Analysis, By Region, 2026 and 2033 (%)  Y-O-Y Growth Analysis, For Regions, 2026 - 2033 o North America  Market Share Analysis, By Country, 2026 and 2033 (%)  Y-O-Y Growth Analysis, By Country, 2026 - 2033 o U.S.  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Canada  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Europe  Market Share Analysis, By Country, 2026 and 2033 (%)  Y-O-Y Growth Analysis, By Country, 2026 - 2033 o U.K.  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Germany  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Italy  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o France  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Spain  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Russia  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Rest of Europe  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Asia Pacific  Market Share Analysis, By Country, 2026 and 2033 (%)  Y-O-Y Growth Analysis, By Country, 2026 - 2033 o China  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o India  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Japan  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o ASEAN  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Australia  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o South Korea  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Rest of Asia Pacific  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Latin America  Market Share Analysis, By Country, 2026 and 2033 (%)  Y-O-Y Growth Analysis, By Country, 2026 - 2033 o Brazil  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Mexico  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Argentina  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Rest of Latin America  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Middle East  Market Share Analysis, By Country, 2026 and 2033 (%)  Y-O-Y Growth Analysis, By Country, 2026 - 2033 o GCC Countries  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Israel  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Rest of Middle East  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Africa  Market Share Analysis, By Country, 2026 and 2033 (%)  Y-O-Y Growth Analysis, By Country, 2026 - 2033 o Northern Africa  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o Central Africa  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) o South Africa  Country Trends  Market Size and Forecast, By Drug Class, 2026 - 2033 (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026 - 2033 (USD Bn) 7. Competitive Landscape o Heat Map Analysis o Company Profiles  Pfizer, Inc. o Company Overview o Product Portfolio o Financial Performance o Key Developments o Market Presence  AstraZeneca plc o Company Overview o Product Portfolio o Financial Performance o Key Developments o Market Presence  Eli Lilly and Company o Company Overview o Product Portfolio o Financial Performance o Key Developments o Market Presence  Allergan plc o Company Overview o Product Portfolio o Financial Performance o Key Developments o Market Presence  GlaxoSmithkline plc o Company Overview o Product Portfolio o Financial Performance o Key Developments o Market Presence  Merck & Co., Inc. o Company Overview o Product Portfolio o Financial Performance o Key Developments o Market Presence  H. Lundbeck A/S o Company Overview o Product Portfolio o Financial Performance o Key Developments o Market Presence  NeuroRx, Inc. o Company Overview o Product Portfolio o Financial Performance o Key Developments o Market Presence  Johnson & Johnson o Company Overview o Product Portfolio o Financial Performance o Key Developments o Market Presence 8. Section o References o Research Methodology o About us and Sales Contact

提及公司

Pfizer, Inc.AstraZeneca plcEli Lilly and CompanyAllergan plcGlaxoSmithKline plcMerck & Co., Inc.Lundbeck A/SNeuroRx, Inc.Johnson & Johnson

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們